 |
PDBsum entry 1a3b
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
1a3b
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Bifunctional peptide boronate inhibitors of thrombin: crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide.
|
 |
|
Authors
|
 |
E.Skordalakes,
S.Elgendy,
C.A.Goodwin,
D.Green,
M.F.Scully,
V.V.Kakkar,
J.M.Freyssinet,
G.Dodson,
J.J.Deadman.
|
 |
|
Ref.
|
 |
Biochemistry, 1998,
37,
14420-14427.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
The affinity of the hirudin49-64 segment for exosite 1 of thrombin has been used
previously to enhance the potency of simple competitive inhibitors [DiMaio, J.,
Gibbs, B., Munn, D., Lefebvre, J. , Ni, F., Konishi, Y. (1990) J. Biol. Chem.
265, 21698-21703., and Maraganore, J. M., Bourdon, P., Jablonski, J.,
Ramachandran, K. L., and Fenton, J. W., II (1990) Biochemistry 29, 7095-7087.].
Using a similar approach, we have enhanced the activity of two active site
directed thrombin inhibitors by attaching this segment via a novel reverse
oriented linker to each of two tripeptide boronate inhibitors. At P1, compound 1
contains an arginine-like, isothiouronium, side chain, while compound 2 contains
an uncharged, bromopropyl residue. Inhibition of human alpha-thrombin by
compound 1 shows slow, tight-binding competitive kinetics (final Ki of 2.2 pM,
k1 of 3.51 x 10(7) M-1 s-1, and k-1 of 1.81 x 10(-)4 s-1). The addition of
hirugen peptide (20 microM) competes for exosite 1 binding and restores the k1
and k-1 to that of the analogous tripeptide, 0.29 x 10(7) M-1 s-1 and 0.13 x
10(-)4 s-1, respectively. Compound 1 has enhanced specificity for thrombin over
trypsin with KiTry/KiThr of approximately 900 compared to the analogous
tripeptide, with KiTry/KiThr of approximately 4. Compound 2 acts as a
competitive inhibitor (KiThr of 0.6 nM) and is highly selective with no effect
on trypsin. Crystallographic analysis of complexes of human alpha-thrombin with
compound 1 (1.8 A) and compound 2 (1.85 A) shows a covalent bond between the
boron of the inhibitor and Ser195 (bond lengths B-O of 1.55 and 1.61 A,
respectively). The isothiouronium group of compound 1 forms bidentate
interactions with Asp189. The P2 and P3 residues of the inhibitors form
interactions with the S2 and S3 sites of thrombin similar to other D-Phe-Pro
based inhibitors [Bode, W., Turk, D., and Karshikov, A. (1992) Protein Sci. 1,
426-471.]. The linker exits the active site cleft of thrombin forming no
interactions, while the binding of Hir49-64 segment to exosite 1 is similar to
that previously described for hirudin [Rydel, T. J., Tulinsky, A., and Bode, W.
(1991) J. Mol. Biol. 221, 583-601.]. Because of the similarity of binding at
each of these sites to that of the analogous peptides added alone, this approach
may be used to improve the inhibitory activity of all types of active site
directed thrombin inhibitors and may also be applicable to the design of
inhibitors of other proteases.
|
 |
|
Secondary reference #1
|
 |
|
Title
|
 |
Structure of the hirulog 3-Thrombin complex and nature of the s' Subsites of substrates and inhibitors.
|
 |
|
Authors
|
 |
X.Qiu,
K.P.Padmanabhan,
V.E.Carperos,
A.Tulinsky,
T.Kline,
J.M.Maraganore,
J.W.Fenton.
|
 |
|
Ref.
|
 |
Biochemistry, 1992,
31,
11689-11697.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
|
 |
|
Secondary reference #2
|
 |
|
Title
|
 |
Structure of the hirugen and hirulog 1 complexes of alpha-Thrombin.
|
 |
|
Authors
|
 |
E.Skrzypczak-Jankun,
V.E.Carperos,
K.G.Ravichandran,
A.Tulinsky,
M.Westbrook,
J.M.Maraganore.
|
 |
|
Ref.
|
 |
J Mol Biol, 1991,
221,
1379-1393.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
|
 |
|
|
|
|
 |